Aditi Kaushik*, Manish Kaushik, Viney Lather and J. S. Dua Pages 1 - 7 ( 7 )
An emerging crisis of antibiotic resistance for microbial pathogens is alarming all the nations, posing a global threat to human health. The production of the metallo-β-lactamase enzyme is the most powerful strategy of bacteria to produce resistance. An efficient way to combat this global health threat is the development of broad/non-specific type of metallo-β-lactamase inhibitors, which can inhibit the different isoforms of the enzyme. Till date, there are no clinically active drugs against metallo- β-lactamase. The lack of efficient drug molecules against MBLs carrying bacteria requires continuous research efforts to overcome the problem of multidrug-resistance bacteria. The present review will discuss the clinically potent molecules against different variants of B1 metallo-β-lactamase.
antibiotic resistance; B1 metallo-β-lactamase; variants
School of Pharmacy, MMU, Sadopur, Ambala, School of Pharmacy, MMU, Sadopur, Ambala, Amity institute of Pharmacy, Amity University, Noida, Shivalik College of Pharmacy, Nangal